TB035: MVA85A- Homologous boosting by heterologous route
Research type
Research Study
Full title
A Phase I trial evaluating mucosal administration of a candidate TB vaccine, MVA85A, as a way to induce potent local cellular immune responses and avoid anti-vector immunity
IRAS ID
131797
Contact name
Helen McShane
Contact email
Eudract number
2013-002020-16
ISRCTN Number
n/a
Clinicaltrials.gov Identifier
n/a
Research summary
TB remains a significant global health problem. There is an urgent need for a better vaccine as the only licensed vaccine,(BCG), protects against severe TB in infancy but less well against lung disease which is how TB spreads.
MVA85A is a new vaccine that improves the effect of BCG in animals. MVA85A is a viral vector vaccine, i.e made from a weakened virus (vector, MVA) that has been altered to contain pieces of DNA from M.tb, the pathogen which causes TB (insert, 85A). To date MVA85A has been given by an injection into the skin but it is likely that delivering MVA85A directly into the lungs by a mist of air (aerosol) would be better, as the route of vaccination then matches the route by which TB is caught.
A problem with virally-vectored vaccines is that individuals build up immunity to the virus base (anti-vector immunity) which makes the vaccine less efficient and also not suitable for re-use (boosting).
Non-human primate data has suggested that aerosolised vaccination avoids anti-vector immunity. This proposed study aims to study the effect of aerosol vaccination of MVA85A on anti-vector and insert (85A) immunity in humans in a clinical trial.REC name
South Central - Oxford A Research Ethics Committee
REC reference
13/SC/0329
Date of REC Opinion
29 Jul 2013
REC opinion
Further Information Favourable Opinion